Evommune (EVMN) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio is the larger company by market cap ($240.8 million vs $232.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | QTTB |
|---|---|---|
| Share price | $6.41 | $8.09 |
| Market cap | $232.63M | $240.83M |
| 1-day change | +3.05% | +1.25% |
| YTD return | -63.67% | +140.66% |
| 1-year return | — | +217.06% |
| 5-year return | — | -92.84% |
| P/E ratio (TTM) | — | 2.57 |
| EPS (TTM) | $-3.75 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $23.57 |
| 52-week low | $6.02 | $1.91 |
| Distance from 52-week high | -80.69% | -65.68% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +276.44% | +389.49% |
| Average volume | 697.98K | 1.38M |
| Shares outstanding | 36.29M | 29.77M |
| Employees | 48 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
EVMN vs QTTB FAQ
Which is bigger, Evommune or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $240.83M compared with $232.63M for Evommune (EVMN).
Are Evommune and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.